- Home
- TDUP vs AVDL Comparison
TDUP vs AVDL Comparison
Compare TDUP & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDUP
- AVDL
- Stock Information
- Founded
- TDUP 2009
- AVDL 2015
- Country
- TDUP United States
- AVDL Ireland
- Employees
- TDUP N/A
- AVDL N/A
- Industry
- TDUP Catalog/Specialty Distribution
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- TDUP Consumer Discretionary
- AVDL Health Care
- Exchange
- TDUP Nasdaq
- AVDL Nasdaq
- Market Cap
- TDUP 927.1M
- AVDL 861.4M
- IPO Year
- TDUP 2021
- AVDL 1996
- Fundamental
- Price
- TDUP $10.51
- AVDL $13.69
- Analyst Decision
- TDUP Buy
- AVDL Strong Buy
- Analyst Count
- TDUP 3
- AVDL 7
- Target Price
- TDUP $12.50
- AVDL $19.00
- AVG Volume (30 Days)
- TDUP 2.5M
- AVDL 1.2M
- Earning Date
- TDUP 08-04-2025
- AVDL 08-07-2025
- Dividend Yield
- TDUP N/A
- AVDL N/A
- EPS Growth
- TDUP N/A
- AVDL N/A
- EPS
- TDUP N/A
- AVDL N/A
- Revenue
- TDUP $277,729,000.00
- AVDL $221,075,000.00
- Revenue This Year
- TDUP $13.36
- AVDL $56.78
- Revenue Next Year
- TDUP $8.46
- AVDL $30.46
- P/E Ratio
- TDUP N/A
- AVDL N/A
- Revenue Growth
- TDUP 20.14
- AVDL 132.35
- 52 Week Low
- TDUP $0.50
- AVDL $6.38
- 52 Week High
- TDUP $11.00
- AVDL $16.66
- Technical
- Relative Strength Index (RSI)
- TDUP 72.53
- AVDL 78.08
- Support Level
- TDUP $9.48
- AVDL $10.79
- Resistance Level
- TDUP $10.92
- AVDL $13.94
- Average True Range (ATR)
- TDUP 0.72
- AVDL 0.65
- MACD
- TDUP 0.14
- AVDL 0.21
- Stochastic Oscillator
- TDUP 86.65
- AVDL 85.83
About TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.